Calculate prostate volume using ultrasound dimensions and estimate PSA density risk.
Quick Answer: A normal prostate volume is typically under 30 cc (or mL). Volume increases with age due to benign enlargement.
- **Normal Size**: Under 30 cc (typical in younger adult males).
- **PSA Density Threshold**: A value of 0.15 ng/mL/cc or higher indicates an elevated risk, which may warrant further clinical follow-up.
Compute estimated prostate volume using standard ellipsoidal ultrasound measurements and analyze PSA density to evaluate health risks.
Entering your Prostate-Specific Antigen (PSA) serum level allows us to calculate your PSA Density, which is a key metric in prostate health screening.
Disclaimer: This calculator provides screening estimates based on standard urological formulas. It is not a substitute for professional medical advice, diagnosis, or treatment.
A medically structured, comprehensive review of the McNeal zonal anatomy, mathematical ultrasound formulations, serum PSA kinetics, and modern urological management strategies.
Understanding the transition, peripheral, and central zones is key to diagnosing benign hyperplasia (BPH) versus peripheral cancers.
Calculating the ratio of serum PSA concentration to ellipsoid volume helps clinicians determine when a prostate biopsy is warranted.
Covers modern treatments ranging from alpha-blockers to minimally invasive water vapor therapies (Rezūm) and laser enucleation (HoLEP).
The prostate is a walnut-sized fibromuscular gland situated within the male pelvis, inferior to the bladder neck and anterior to the rectum. It encapsulates the proximal portion of the urethra, known as the prostatic urethra. Anatomically, the gland is divided using the **McNeal Zonal Classification**, which describes four distinct structural zones:
Surrounds the proximal urethra and accounts for 5-10% of gland volume in young men. This zone is the exclusive site of origin for Benign Prostatic Hyperplasia (BPH).
Makes up roughly 70% of the normal glandular volume, wrapping around the posterior and lateral aspects. Approximately 75-80% of all prostate cancers originate here.
Surrounds the ejaculatory ducts and constitutes about 20-25% of the gland. It is histologically distinct and is rarely the site of primary pathology.
Physiologically, the prostate functions as an exocrine gland. It secretes an alkaline fluid that constitutes approximately 30% of the total seminal volume. This secretion contains essential enzymes, including zinc, citric acid, acid phosphatase, and **Prostate-Specific Antigen (PSA)**. The alkaline nature of prostatic fluid helps neutralize the acidic environment of the female vaginal tract, preserving sperm motility and viability.
Benign Prostatic Hyperplasia (BPH) is an age-related, non-malignant proliferation of stromal and epithelial cells within the transition zone of the prostate. The molecular pathogenesis of BPH is primarily driven by the accumulation of **dihydrotestosterone (DHT)**, a potent androgen synthesized from circulating testosterone by the intracellular enzyme **5-alpha-reductase type 2**.
As men age, stromal and epithelial cells in the transition zone remain sensitive to DHT, which promotes local growth factors (such as FGF-2 and TGF-β) while downregulating apoptotic pathways. This cellular hyperplasia leads to the formation of discrete nodules that compress the surrounding peripheral zone and constrict the prostatic urethra.
This anatomical constriction results in **bladder outlet obstruction (BOO)**, which presents clinically as **Lower Urinary Tract Symptoms (LUTS)**. LUTS is divided into two primary categories:
Ultrasound imaging (typically Transrectal Ultrasound, TRUS) remains the gold standard for measuring prostate size. Because the prostate is three-dimensional, its volume is calculated using the formula for a **prolate ellipsoid**. The urologist or radiologist obtains three orthogonal diameters:
The general formula for calculating the volume of an ellipsoid is:
Simplifying this algebraic expression by grouping the constants yields:
This coefficient of 0.5236 is the standard scaling factor used in most commercial ultrasound consoles and clinical software.
In some clinical settings, a simplified coefficient of 0.52 is used. This minor variation represents a prolate spheroid model and is often used for quick manual calculations. While the difference is clinically negligible (typically less than 1% variance), the standard ellipsoid factor of 0.5236 remains the preferred method for diagnostic accuracy.
Prostate-Specific Antigen (PSA) is a glycoprotein enzyme secreted by the epithelial cells of the prostate. It liquifies semen in the seminal coagulum to allow sperm to swim freely. Under normal conditions, only small amounts of PSA leak into the blood.
However, disruption of the prostate's cellular architecture—caused by prostate cancer, benign prostatic hyperplasia (BPH), inflammation (prostatitis), or urinary retention—can cause more PSA to enter the bloodstream, raising serum PSA levels.
Because both BPH and prostate cancer raise serum PSA, a simple PSA blood test can sometimes produce false-positive results. To improve diagnostic accuracy, clinicians calculate **PSA Density (PSAD)**:
Since malignant prostate tissue produces more PSA per gram than benign hyperplastic tissue, a high PSA density suggests a greater likelihood of cancer.
Clinical studies show that a PSA density threshold of 0.15 ng/mL/cc is a helpful tool for risk stratification.
Management of prostate enlargement depends on the severity of symptoms, prostate volume, and PSA density. Treatment options include:
For men with mild symptoms and normal PSA density, regular checkups (including digital rectal exams and PSA tests) are often sufficient to monitor the condition.
Track cardiovascular, body index, and vital statistics with clinical precision.